-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
- Cosmetic Ingredient
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
Small molecule drugs have great potential in the current treatment of tumors and non-tumor diseases.
In recent years, with the expansion of medical insurance coverage, the continuous enhancement of residents' ability to pay, and the support of a series of favorable medical innovation policies, small molecule drugs While the market size is expanding, more and more pharmaceutical companies are also accelerating their deployment in this field
.
For example, recently, Hansoh Pharmaceutical Group announced that its wholly-owned subsidiaries Hansoh (Shanghai) Health and Jiangsu Hansoh Pharmaceuticals (collectively referred to as licensees) entered into an exclusive license agreement with NiKang Therapeutics
Inc.
According to the license agreement, the licensee will receive an exclusive license from NiKang Therapeutics to develop and commercialize NKT2152 for the treatment of tumors in China, including Hong Kong, Macau and Taiwan
.
Licensees will pay an upfront payment of $15 million and potential payments of up to $203 million in development, registration and sales-based commercialization milestones, as well as tiered royalties based on net sales
.
It is understood that NKT2152 is a small molecule that inhibits HIF-2α, and is currently conducting a phase I/II dose escalation and expansion trial (NCT05119335)
.
The trial was designed to evaluate safety, tolerability, pharmacokinetics, pharmacodynamics and clinical activity in patients with advanced clear cell renal cell carcinoma (ccRCC)
.
Industry analysts believe that cooperation has actually become a means for many pharmaceutical companies to deploy in the field of small molecule drugs
.
In recent years, news of cooperation between companies in the industry in the field of small molecules has been continuously coming
.
For example, on September 8 last year, Huadong Medicine announced the establishment of a partnership with Insilico to jointly accelerate the research and development of innovative small molecule drugs in the field of oncology
.
According to the agreement, Huadong Medicine and Insilicon will start a new drug discovery project with the cooperation of the scientific research teams of both parties
.
On August 31, Bichen Medicine and Sunshine Guojian, which focus on the development of small molecule targeted drugs that can break through the blood-brain barrier, jointly announced a strategic cooperation agreement
.
According to the agreement, both parties will make full use of their respective technological and resource advantages to strengthen development and cooperation in new products and technologies
.
At the same time, the two parties will also conduct extensive cooperation on the clinical development and registration application of innovative anti-tumor drug combinations in the Chinese market
.
It is worth mentioning that in addition to cooperation, many companies focusing on the research and development of new small molecule drugs are still accelerating financing in order to accelerate the development and implementation of innovative results
.
As of February 8 this year, Yossen Jianheng announced the completion of more than 200 million yuan in Series A financing
.
This round of financing was led by Shenzhen Sharing Investment, followed by Zhang Jiang Haoheng and Yingke Capital.
The original shareholders continued to participate in this round of investment
.
It is reported that the funds raised in this round will be used to carry out and accelerate the global clinical trials of UA007 and UA021, the development of small-molecule drugs for multiple new targets, and the development of specific double-antibody drugs
.
On February 14, Qinhao Pharmaceutical (Suzhou) Co.
, Ltd.
(hereinafter referred to as "Qinhao Pharmaceutical") also announced that the company has completed a series B financing of several hundred million yuan
.
According to the data, Qinhao Pharmaceutical is a global innovative biopharmaceutical company, focusing on the development of original anti-tumor small molecule new drugs
.
At present, the company has built and improved four new drug research and development centers: innovation research center, drug design and discovery center, new drug screening and evaluation center, and clinical development center, and has built a product research and development pipeline with more than 10 projects
.
In general, as many pharmaceutical companies have entered the field of small molecule drugs, and capital continues to increase, it is helping the entire small molecule drug market to further develop
.
It is understood that data from Frost & Sullivan earlier showed that China's small molecule tumor targeted therapy market has increased from 8.
5 billion yuan in 2016 to 37.
5 billion yuan in 2020.
It will reach 120.
5 billion yuan, and will further increase to 207 billion yuan in 2030
.
In this context, the industry expects that companies in this field may usher in more development opportunities
.
Disclaimer: Under no circumstances does the information or opinions expressed in this article constitute investment advice to anyone
.
In recent years, with the expansion of medical insurance coverage, the continuous enhancement of residents' ability to pay, and the support of a series of favorable medical innovation policies, small molecule drugs While the market size is expanding, more and more pharmaceutical companies are also accelerating their deployment in this field
.
For example, recently, Hansoh Pharmaceutical Group announced that its wholly-owned subsidiaries Hansoh (Shanghai) Health and Jiangsu Hansoh Pharmaceuticals (collectively referred to as licensees) entered into an exclusive license agreement with NiKang Therapeutics
Inc.
According to the license agreement, the licensee will receive an exclusive license from NiKang Therapeutics to develop and commercialize NKT2152 for the treatment of tumors in China, including Hong Kong, Macau and Taiwan
.
Licensees will pay an upfront payment of $15 million and potential payments of up to $203 million in development, registration and sales-based commercialization milestones, as well as tiered royalties based on net sales
.
It is understood that NKT2152 is a small molecule that inhibits HIF-2α, and is currently conducting a phase I/II dose escalation and expansion trial (NCT05119335)
.
The trial was designed to evaluate safety, tolerability, pharmacokinetics, pharmacodynamics and clinical activity in patients with advanced clear cell renal cell carcinoma (ccRCC)
.
Industry analysts believe that cooperation has actually become a means for many pharmaceutical companies to deploy in the field of small molecule drugs
.
In recent years, news of cooperation between companies in the industry in the field of small molecules has been continuously coming
.
For example, on September 8 last year, Huadong Medicine announced the establishment of a partnership with Insilico to jointly accelerate the research and development of innovative small molecule drugs in the field of oncology
.
According to the agreement, Huadong Medicine and Insilicon will start a new drug discovery project with the cooperation of the scientific research teams of both parties
.
On August 31, Bichen Medicine and Sunshine Guojian, which focus on the development of small molecule targeted drugs that can break through the blood-brain barrier, jointly announced a strategic cooperation agreement
.
According to the agreement, both parties will make full use of their respective technological and resource advantages to strengthen development and cooperation in new products and technologies
.
At the same time, the two parties will also conduct extensive cooperation on the clinical development and registration application of innovative anti-tumor drug combinations in the Chinese market
.
It is worth mentioning that in addition to cooperation, many companies focusing on the research and development of new small molecule drugs are still accelerating financing in order to accelerate the development and implementation of innovative results
.
As of February 8 this year, Yossen Jianheng announced the completion of more than 200 million yuan in Series A financing
.
This round of financing was led by Shenzhen Sharing Investment, followed by Zhang Jiang Haoheng and Yingke Capital.
The original shareholders continued to participate in this round of investment
.
It is reported that the funds raised in this round will be used to carry out and accelerate the global clinical trials of UA007 and UA021, the development of small-molecule drugs for multiple new targets, and the development of specific double-antibody drugs
.
On February 14, Qinhao Pharmaceutical (Suzhou) Co.
, Ltd.
(hereinafter referred to as "Qinhao Pharmaceutical") also announced that the company has completed a series B financing of several hundred million yuan
.
According to the data, Qinhao Pharmaceutical is a global innovative biopharmaceutical company, focusing on the development of original anti-tumor small molecule new drugs
.
At present, the company has built and improved four new drug research and development centers: innovation research center, drug design and discovery center, new drug screening and evaluation center, and clinical development center, and has built a product research and development pipeline with more than 10 projects
.
In general, as many pharmaceutical companies have entered the field of small molecule drugs, and capital continues to increase, it is helping the entire small molecule drug market to further develop
.
It is understood that data from Frost & Sullivan earlier showed that China's small molecule tumor targeted therapy market has increased from 8.
5 billion yuan in 2016 to 37.
5 billion yuan in 2020.
It will reach 120.
5 billion yuan, and will further increase to 207 billion yuan in 2030
.
In this context, the industry expects that companies in this field may usher in more development opportunities
.
Disclaimer: Under no circumstances does the information or opinions expressed in this article constitute investment advice to anyone
.
